Table 2 Demographics of randomized patients

Age(mean, years)

39.7 ± 4.1

39.6 ± 4.1

0.580

Stage

 I

178 (27.2 %)

169 (26.7 %)

0.977

 II

335 (51.1 %)

332 (52.4 %)

 III

121 (18.5 %)

113 (17.8 %)

 Unidentified

21 (3.2 %)

20 (3.2 %)

Lymph node status

 Negative

279 (42.6 %)

275 (43.4 %)

0.927

 Positive

371 (56.6 %)

355 (56.0 %)

 Unidentified

5 (0.8 %)

4 (0.6 %)

Histology

 Invasive ductal carcinoma

573 (87.5 %)

560 (88.3 %)

0.917

 Invasive lobular carcinoma

32 (4.9 %)

26 (4.1 %)

 Others

42 (6.4 %)

41 (6.5 %)

 Unidentified

8 (1.2 %)

7 (1.1 %)

Histologic grade

 G1

95(14.5 %)

118 (18.6 %)

0.229

 G2

359 (54.8 %)

323 (50.9 %)

 G3

160 (24.4 %)

151 (23.8 %)

 Unidentified

41(6.3 %)

42 (6.6 %)

Chemotherapy regimen

 Anthracycline + cyclophosphamide

184 (28.1 %)

185 (29.2 %)

0.782

 Anthracycline + cyclophosphamide followed by taxane

324 (49.5 %)

318 (50.2 %)

 Anthracycline + taxane

30 (4.6 %)

29 (4.6 %)

 5-fluorouracil + anthracycline + cyclophosphamide

74 (11.3 %)

73(11.5 %)

 Others

21 (3.2 %)

14(2.2 %)

 Unidentified

22 (3.4 %)

15 (2.4 %)

Operation

 Total mastectomy

268 (40.9 %)

248 (39.1 %)

0.762

 Breast conserving surgery

382 (58.3 %)

382 (60.3 %)

 Unidentified

5 (0.8 %)

4 (0.6 %)